Literature DB >> 18569776

Development and validation of the Affective Self Rating Scale for manic, depressive, and mixed affective states.

Mats Adler1, Benny Liberg, Stig Andersson, Göran Isacsson, Jerker Hetta.   

Abstract

Most rating scales for affective disorders measure either depressive or hypomanic/manic symptoms and there are few scales for hypomania/mania in a self-rating format. We wanted to develop and validate a self-rating scale for comprehensive assessment of depressive, manic/hypomanic and mixed affective states. We developed an 18-item self-rating scale starting with the DSM-IV criteria for depression and mania, with subscales for depression and mania. The scale was evaluated on 61 patients with a diagnosis of affective disorder, predominantly bipolar disorder type I, using Montgomery-Asberg Depression Rating Scale (MADRS), Hypomania Interview Guide-Clinical version (HIGH-C) and Clinical Global Impression scale, modified for bipolar patients (CGI-BP) as reference scales. Internal consistency of the scale measured by Cronbach's alpha was 0.89 for the depression subscale and 0.91 for the mania subscale. Spearman's correlation coefficients (two-tailed) between the depression subscale and MADRS was 0.74 (P<0.01) and between mania subscale and HIGH-C 0.80 (P<0.01). A rotated factor analysis of the scale supported the separation of symptoms in the mania and depression subscale. We established that the self-rating scales sensitivity to identify mixed states, with combined cut-offs on the MADRS and HIGH-C as reference, was 0.90 with a specificity of 0.71. The study shows that the Affective Self Rating Scale is highly correlated with ratings of established interview scales for depression and mania and that it may aid the detection of mixed affective states.

Entities:  

Mesh:

Year:  2008        PMID: 18569776     DOI: 10.1080/08039480801960354

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  8 in total

1.  Systematic Review of Symptom Assessment Measures for Use in Measurement-Based Care of Bipolar Disorders.

Authors:  Joseph M Cerimele; Simon B Goldberg; Christopher J Miller; Stephen W Gabrielson; John C Fortney
Journal:  Psychiatr Serv       Date:  2019-02-05       Impact factor: 3.084

Review 2.  Activated depression: mixed bipolar disorder or agitated unipolar depression?

Authors:  Alan C Swann
Journal:  Curr Psychiatry Rep       Date:  2013-08       Impact factor: 5.285

3.  Clinician preferences for using bipolar disorder symptom severity and quality of life scales for measurement-based care.

Authors:  Joseph M Cerimele; Brittany E Blanchard; Jared M Bechtel; John C Fortney
Journal:  Gen Hosp Psychiatry       Date:  2021-08-09       Impact factor: 3.238

4.  An item response theory evaluation of three depression assessment instruments in a clinical sample.

Authors:  Mats Adler; Jerker Hetta; Göran Isacsson; Ulf Brodin
Journal:  BMC Med Res Methodol       Date:  2012-06-21       Impact factor: 4.615

Review 5.  The functional anatomy of psychomotor disturbances in major depressive disorder.

Authors:  Benny Liberg; Christoffer Rahm
Journal:  Front Psychiatry       Date:  2015-03-10       Impact factor: 4.157

6.  Internet-Based Cognitive Behavioral Therapy for Residual Symptoms in Bipolar Disorder Type II: A Single-Subject Design Pilot Study.

Authors:  Fredrik Holländare; Annsofi Eriksson; Lisa Lövgren; Mats B Humble; Katja Boersma
Journal:  JMIR Res Protoc       Date:  2015-04-23

7.  Self-report depression screening measures for older Hispanic/Latin American adults: A PRISMA systematic review.

Authors:  Andrea Ochoa Lopez; Michelle N Martinez; Joshua M Garcia; Mark E Kunik; Luis D Medina
Journal:  J Affect Disord       Date:  2021-06-25       Impact factor: 4.839

8.  Saving time and money: a validation of the self ratings on the prospective NIMH Life-Chart Method (NIMH-LCM).

Authors:  Christoph Born; Benedikt L Amann; Heinz Grunze; Robert M Post; Lars Schärer
Journal:  BMC Psychiatry       Date:  2014-05-07       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.